Marcel Zins-Ritter
Research Subjects
Marcel Zins-Ritter has a total of 8 co-authors. Here are the top co-authors by number of shared publications:
- Amandine Luquiens
Univ. Montpellier, Department of Addiction, CHU Nîmes, Nîmes, France
1 shared publication - Bruno Falissard
CESP, INSERM U1018, Université Paris-Saclay, 94800 Villejuif, France
1 shared publication - Chantal Henry
Université de Paris Cité, Paris, France; GHU Psychiatrie & Neurosciences, Paris, France
1 shared publication - Christophe Lançon
Pôle Psychiatrie, Centre Expert Dépression Résistante FondaMental, CHU La Conception, Marseille, France
1 shared publication - Elena Perrin
Eli Lilly, 13, Rue Pages, 92158 Suresnes Cedex, Paris, France
1 shared publication - Hélène Sapin
Lilly France, Neuilly-sur-Seine cedex, France
1 shared publication
Latest Publications
- Open Access
- 13 March 2013
- Published by Springer Nature in BMC Psychiatry
- Vol. 13 (1) , 79
Inhibition/activation in bipolar disorder: validation of the Multidimensional Assessment of Thymic States scale (MAThyS)
Background: One of the major issues in clinical practice is the accurate differential diagnosis between mixed states and depression, often leading to inappropriate prescriptions of antidepressants in mixed states, and as a consequence, increasing the risk of manic switch and suicide. In order to better define the spectrum of mixed states, it may be useful to develop a dimensional approach. In this context, the MAThyS (Multidimensional Assessment of Thymic States) scale was built to assess activation/inhibition levels in all bipolar mood episodes, and to determine whether a clinical description in terms of activation/inhibition can help better define bipolar states with which both manic and depressive symptoms are associated. The aim of this paper is the validation of the MAThyS scale in 141 bipolar patients in acute states (manic, hypomanic, mixed, or depressive). Methods: The validation of the MAThyS scale was the primary outcome of this 24-week, phase III, open-label, olanzapine single-arm clinical trial. Principal component, factorial analysis, and Cronbach’s coefficient calculation (internal consistency) were performed. Concurrent validity (correlations with 17-item Hamilton Depression Rating Scale [HAMD-17], Hamilton Anxiety Rating Scale [HAMA], and Young Mania Rating Scale [YMRS]) and responsiveness to the clinical intervention were assessed (change in MAThyS scale and effect size) at 6 and 24 weeks. Results: Scree plot of eigenvalues identified a 2-dimension structure (“activation/inhibition level” and “emotional component”). Psychometric properties were good: Cronbach’s coefficient was >0.9. Concurrent validity was good with low correlation (−0.19) with the HAMA scale and a higher correlation at baseline with the YMRS (0.72) and HAMD-17(−0.43). As expected, the activation state was predominant in manic, hypomanic, and mixed states while inhibition was predominant in depressive states. MAThyS score improvement was observed (effect size: -0.3 at 6 and 24 weeks). Conclusions: The MAThyS demonstrated good psychometric properties. The MAThyS scale may help clinicians to better discriminate and follow bipolar episodes, especially the broad spectrum of mixed episodes. Trial registration: ClinicalTrials.gov registration identification number: NCT#002592722
- 13 March 2013
- Published by Springer Nature in BMC Psychiatry
- Vol. 13 (1) , 79
Open AccessInhibition/activation in bipolar disorder: validation of the Multidimensional Assessment of Thymic States scale (MAThyS)
Background: One of the major issues in clinical practice is the accurate differential diagnosis between mixed states and depression, often leading to inappropriate prescriptions of antidepressants in mixed states, and as a consequence, increasing the risk of manic switch and suicide. In order to better define the spectrum of mixed states, it may be useful to develop a dimensional approach. In this context, the MAThyS (Multidimensional Assessment of Thymic States) scale was built to assess activation/inhibition levels in all bipolar mood episodes, and to determine whether a clinical description in terms of activation/inhibition can help better define bipolar states with which both manic and depressive symptoms are associated. The aim of this paper is the validation of the MAThyS scale in 141 bipolar patients in acute states (manic, hypomanic, mixed, or depressive). Methods: The validation of the MAThyS scale was the primary outcome of this 24-week, phase III, open-label, olanzapine single-arm clinical trial. Principal component, factorial analysis, and Cronbach’s coefficient calculation (internal consistency) were performed. Concurrent validity (correlations with 17-item Hamilton Depression Rating Scale [HAMD-17], Hamilton Anxiety Rating Scale [HAMA], and Young Mania Rating Scale [YMRS]) and responsiveness to the clinical intervention were assessed (change in MAThyS scale and effect size) at 6 and 24 weeks. Results: Scree plot of eigenvalues identified a 2-dimension structure (“activation/inhibition level” and “emotional component”). Psychometric properties were good: Cronbach’s coefficient was >0.9. Concurrent validity was good with low correlation (−0.19) with the HAMA scale and a higher correlation at baseline with the YMRS (0.72) and HAMD-17(−0.43). As expected, the activation state was predominant in manic, hypomanic, and mixed states while inhibition was predominant in depressive states. MAThyS score improvement was observed (effect size: -0.3 at 6 and 24 weeks). Conclusions: The MAThyS demonstrated good psychometric properties. The MAThyS scale may help clinicians to better discriminate and follow bipolar episodes, especially the broad spectrum of mixed episodes. Trial registration: ClinicalTrials.gov registration identification number: NCT#002592722